View Older Stories View More Recent Stories

Nov 20, 2023 06:45AM Merck to Participate in the 6th Annual Evercore ISI HealthCONx Conference
Nov 16, 2023 05:41PM Merck (MRK) Announces FDA Approval of KEYTRUDA Plus Chemotherapy as First-Line Treatment for Locally Advanced Unresectable or Metastatic HER2-Negative Gastric or Gastroesophageal Junction (GEJ) Adenoc
Nov 16, 2023 05:40PM FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy as First-Line Treatment for Locally Advanced Unresectable or Metastatic HER2-Negative Gastric or Gastroesophageal Junction (GEJ) Ade
Nov 10, 2023 07:41AM Merck (MRK) Receives Positive EU CHMP Opinion for KEYTRUDA Plus Gemcitabine and Cisplatin
Nov 10, 2023 07:40AM Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Gemcitabine and Cisplatin as First-Line Treatment for Locally Advanced Unresectable or Metastatic Biliary Tract Cancer
Nov 8, 2023 04:01PM Ligand Reports Third Quarter 2023 Financial Results
Nov 8, 2023 06:45AM Merck to Participate in the Jefferies London Healthcare Conference
Nov 1, 2023 06:50AM Merck to Participate in the UBS BioPharma Conference
Nov 1, 2023 06:46AM Merck (MRK) Announces FDA Approval of KEYTRUDA Plus Gemcitabine and Cisplatin as Treatment for Patients With Locally Advanced Unresectable or Metastatic Biliary Tract Cancer
Nov 1, 2023 06:45AM FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Gemcitabine and Cisplatin as Treatment for Patients With Locally Advanced Unresectable or Metastatic Biliary Tract Cancer
Nov 1, 2023 06:30AM KEYTRUDA® (pembrolizumab) Significantly Improved Overall Survival (OS) Versus Placebo as Adjuvant Therapy for Certain Patients With Renal Cell Carcinoma (RCC) Following Nephrectomy
Oct 26, 2023 06:30AM Merck Announces Third-Quarter 2023 Financial Results
Oct 22, 2023 10:30AM KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) Reduced Risk of Death by More Than Half Versus Chemotherapy in Patients With Previously Untreated Locally Advanced or Metastatic Urot
Oct 21, 2023 08:45AM Merck’s WELIREG® (belzutifan) Significantly Improved Progression-Free Survival and Objective Response Rates Versus Everolimus in Certain Previously Treated Patients With Advanced Renal Cell Carcino
Oct 20, 2023 10:00AM Merck’s KEYTRUDA® (pembrolizumab) Plus Concurrent Chemoradiotherapy Significantly Improved Progression-Free Survival (PFS) Versus Concurrent Chemoradiotherapy Alone in Newly Diagnosed, High-Risk Lo
Oct 20, 2023 08:03AM Merck (MRK) Reports KEYTRUDA Plus Trastuzumab and Chemotherapy Significantly Improved Progression-Free Survival (PFS) Versus Trastuzumab and Chemotherapy in First-Line HER2-Positive Advanced Gastric o
Oct 20, 2023 08:02AM Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy Showed Statistically Significant Improvement in Pathological Complete Response (pCR) Rate as Neoadjuvant Therapy Versus Chemotherapy in High-Risk
Oct 20, 2023 08:01AM KEYTRUDA® (pembrolizumab) Plus Trastuzumab and Chemotherapy Significantly Improved Progression-Free Survival (PFS) Versus Trastuzumab and Chemotherapy in First-Line HER2-Positive Advanced Gastric or
Oct 20, 2023 08:00AM KEYTRUDA® (pembrolizumab) Plus Chemotherapy Before Surgery and Continued as Single Agent After Surgery Reduced Risk of Death by 28% Versus Pre-Operative Chemotherapy in Resectable Stage II, IIIA or I
Oct 20, 2023 07:07AM Merck (MRK) in cancer drug deal with Daiichi Sankyo for $5.5 billion upfront, and up to $22 billion total
Oct 19, 2023 07:30PM Daiichi Sankyo and Merck Announce Global Development and Commercialization Collaboration for Three Daiichi Sankyo DXd ADCs
Oct 17, 2023 06:45AM Merck (MRK) Receives Positive EU CHMP Opinion for PREVYMIS for Prevention of CMV Disease in High-Risk Adult Kidney Transplant Recipients and Extended 200-Day Dosing in Adult HSCT Recipients at Risk fo
Oct 17, 2023 06:45AM Merck Receives Positive EU CHMP Opinion for PREVYMIS® for Prevention of CMV Disease in High-Risk Adult Kidney Transplant Recipients and Extended 200-Day Dosing in Adult HSCT Recipients at Risk for La
Oct 16, 2023 07:36PM Merck (MRK) Announces FDA Approval of KEYTRUDA for Treatment of Patients With Resectable NSCLC in Combination With Chemotherapy
Oct 16, 2023 07:00PM FDA Approves KEYTRUDA® (pembrolizumab) for Treatment of Patients With Resectable (T≥4 cm or N+) NSCLC in Combination With Chemotherapy as Neoadjuvant Treatment, Then Continued as a Single Agent as
Oct 16, 2023 06:45AM Merck (MRK) Announces EU Approval of KEYTRUDA as Adjuvant Treatment for Adults With Non-Small Cell Lung Cancer at High Risk of Recurrence Following Complete Resection and Platinum-Based Chemotherapy
Oct 16, 2023 06:45AM European Commission Approves KEYTRUDA® (pembrolizumab) as Adjuvant Treatment for Adults With Non-Small Cell Lung Cancer at High Risk of Recurrence Following Complete Resection and Platinum-Based Chem
Oct 13, 2023 07:45AM Merck (MRK) Receives Positive EU CHMP Opinion for KEYTRUDA Plus Chemotherapy as First-Line Treatment for HER2-Negative Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma Expressing PD-
Oct 13, 2023 07:45AM Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Chemotherapy as First-Line Treatment for HER2-Negative Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma Ex
Oct 10, 2023 06:46AM Merck (MRK) Highlights Innovative Oncology Portfolio and Pipeline
Oct 10, 2023 06:45AM Merck Highlights Innovative Oncology Portfolio and Pipeline at ESMO Congress 2023 Underscoring Commitment to Advancing Cancer Research and Improving Patient Outcomes Across Multiple Stages of Disease
Oct 10, 2023 06:31AM Merck (MRK) Reports KEYNOTE-671 Trial Meets Dual Primary Endpoint
Oct 10, 2023 06:30AM Merck Announces Pivotal KEYNOTE-671 Trial Meets Dual Primary Endpoint of Overall Survival (OS) in Resectable Stage II, IIIA or IIIB Non-Small Cell Lung Cancer (NSCLC)
Oct 5, 2023 07:01AM Merck (MRK) KEYTRUDA Met Primary Endpoint of DFS in Certain Patients With MIUC After Surgery
Oct 5, 2023 07:00AM Merck’s KEYTRUDA® (pembrolizumab) Met Primary Endpoint of Disease-Free Survival (DFS) in Certain Patients With Muscle-Invasive Urothelial Carcinoma (MIUC) After Surgery
Oct 5, 2023 06:45AM Merck to Hold Third-Quarter 2023 Sales and Earnings Conference Call Oct. 26
Sep 28, 2023 06:46AM Merck (MRK) Granted FDA Priority Review for Sotatercept
Sep 28, 2023 06:45AM Merck Receives Priority Review from FDA for New Biologics License Application for Sotatercept, an Activin Signaling Inhibitor to Treat Adults with Pulmonary Arterial Hypertension (PAH)
Sep 26, 2023 04:00AM MilliporeSigma to Become First Provider to Offer Fully Integrated mRNA Services
Sep 22, 2023 06:46AM Merck (MRK) and Eisai Provide Update on Two Phase 3 Trials Evaluating KEYTRUDA Plus LENVIMA in Patients With Certain Types of Metastatic Non-Small Cell Lung Cancer
Sep 22, 2023 06:45AM Merck and Eisai Provide Update on Two Phase 3 Trials Evaluating KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) in Patients With Certain Types of Metastatic Non-Small Cell Lung Cancer
Sep 22, 2023 06:00AM Merck (MRK) Announces Phase 3 KEYNOTE-A39/EV-302 Trial Met Dual Primary Endpoints of Overall Survival and Progression-Free Survival
Sep 22, 2023 06:00AM Merck Announces Phase 3 KEYNOTE-A39/EV-302 Trial Met Dual Primary Endpoints of Overall Survival (OS) and Progression-Free Survival (PFS) in Certain Patients With Previously Untreated Locally Advanced
Sep 20, 2023 06:45AM Merck (MRK) Granted FDA Priority Review for KEYTRUDA Plus Concurrent Chemoradiotherapy as Treatment for Patients With Newly Diagnosed High-Risk Locally Advanced Cervical Cancer
Sep 20, 2023 06:45AM FDA Grants Priority Review to Merck’s Application for KEYTRUDA® (pembrolizumab) Plus Concurrent Chemoradiotherapy as Treatment for Patients With Newly Diagnosed High-Risk Locally Advanced Cervical
Sep 19, 2023 06:45AM Merck (MRK) Announces FDA Acceptance for Priority Review of NDA for WELIREG
Sep 19, 2023 06:45AM FDA Accepts for Priority Review Merck’s Supplemental New Drug Application for WELIREG® (belzutifan) in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma (RCC)
Sep 15, 2023 09:10AM Merck (MRK) Receives Positive EU CHMP Opinion for KEYTRUDA as Adjuvant Treatment for Adults with Non-Small Cell Lung Cancer at High Risk of Recurrence Following Complete Resection and Platinum-Based C
Sep 15, 2023 09:10AM Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) as Adjuvant Treatment for Adults with Non-Small Cell Lung Cancer at High Risk of Recurrence Following Complete Resection and Plat
Sep 11, 2023 07:45AM Merck (MRK) Presents New Analyses Supporting the Promising Potential of Sotatercept, its Investigational Medicine for Adults with PAH
View More Recent Stories View Older Stories